Evidence map›Paper›PMID 41521162›Full record

SynthesisCancer medicine2026

Association of Time to Antibiotics With Outcome in Pediatric Patients Receiving Chemotherapy for Cancer With Fever in Neutropenia-An International Individual Patient Data Meta-Analysis.

Amelie L Salomon, Roland A Ammann, Catherine Aftandilian, Konrad Bochennek, Eva Brack, Lee Dupuis, Caitlin W Elgarten, Adam Esbenshade, Gabrielle M Haeusler, Mia Karamatsu and 7 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amelie L SalomonPediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Roland A AmmannStatConsult Ammann, Burgdorf, Switzerland.
Catherine AftandilianPediatric Hematology/Oncology, Stanford University, Palo Alto, California, USA.
Konrad BochennekPediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe University, Frankfurt, Germany.
Eva BrackPediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Lee DupuisDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Caitlin W ElgartenDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Adam EsbenshadeDepartment of Pediatrics, Vanderbilt University Medical Center and the Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-0154-4996
Gabrielle M HaeuslerDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Mia KaramatsuPediatric Emergency Medicine, Stanford University, Palo Alto, California, USA.
Mette B MoensterDepartment of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Bob PhillipsCentre for Reviews and Dissemination, University of York, York, UK.ORCID https://orcid.org/0000-0002-4938-9673
Emily SchaefferDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Lillian SungDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0951-3091
Athanasios Tragiannidis2nd Paediatric Department, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
Nadja H VissingDepartment of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Christa KoenigPediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-9965-5183

Funding

Inselspital, Universitätsspital Bern 2024/2025 Young Investigator Grant
6 · The paper itself

Abstract

purposeFever in neutropenia (FN) is a potentially lethal complication of chemotherapy for cancer. Prompt administration of broad-spectrum antibiotics is standard of care. Despite conflicting results on the association of time to antibiotics (TTA) with outcomes, TTA limits are used as FN quality measure both in adult and pediatric oncology. This individual patient data (IPD) meta-analysis studied the association between TTA and outcomes in pediatric patients with FN. PATIENTS AND

methodsIPD on TTA in pediatric patients with FN receiving chemotherapy for any malignancy was collected internationally. Three-level mixed binomial logistic regression analyzed the association of TTA with safety relevant events (SRE; death, admission to intensive care unit [ICU], bacteremia), primarily in patients with severe disease at presentation and secondarily in all patients.

resultsData on 4006 FN episodes in 2073 patients, diagnosed 2016-2023, were reported from 15 study sites in eight countries. Median TTA was 61 min overall and 53 min in the 345 (8.6%) episodes with severe disease at presentation. Among these with severe disease, an SRE was reported in 119 (34%) episodes. Longer TTA (> 60 vs. ≤ 60 min) was associated with less SRE (odds ratio, 0.41; 95% CI, 0.24-0.70). This primary finding was confirmed in secondary and additional exploratory analyses.

conclusionThis large, international and adequately powered IPD meta-analysis found no association between shorter TTA and improved clinical outcomes in pediatric patients with FN. This finding was consistent across analyses. These results challenge the continued use of TTA limits as a quality measure for pediatric oncology centers.

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaFeverNeoplasmsNeutropeniaTime-to-TreatmentAdolescentChildChild, PreschoolFemaleHumansInfantMaleTreatment OutcomeAnti-Bacterial AgentsAntineoplastic Agentsantibiotic administrationfebrile neutropeniafever in neutropeniapediatric oncologytime to antibiotics

Identifiers

PMID41521162
PMCPMC12790953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.